Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling

Biochemical Pharmacology

Volumn 79, Issue 9, 2010, Pages 1300-1309

  Martinez, Laurène ^a,b   Berenguer, Marion ^a,b   Bruce, M Christine ^a,b   Le Marchand Brustel, Yannick ^a,b   Govers, Roland ^a,b  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Adipocyte; Diabetes type 2; GLUT4; Insulin resistance; Rosiglitazone; Thiazolidinedione

Indexed keywords

FAT DROPLET; GLUCOSE TRANSPORTER 4; INSULIN; ROSIGLITAZONE; TRANSFERRIN RECEPTOR;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL MEMBRANE; CELL STRAIN 3T3; CELL SURFACE; CONTROLLED STUDY; ENDOSOME; GENE EXPRESSION; GENE TRANSLOCATION; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSOMES; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICE; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 77649189367     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.12.013     Document Type: Article

References (43)

1. Martens F.M., Visseren F.L., Lemay J., de Koning E.J., and Rabelink T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62 (2002) 1463-1480
2. Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract 60 (2006) 1272-1280
3. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 24 (2008) 14-26
4. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
5. Hallakou S., Doare L., Foufelle F., Kergoat M., Guerre-Millo M., Berthault M.F., et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46 (1997) 1393-1399
6. Hallakou S., Foufelle F., Doare L., Kergoat M., and Ferre P. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia 41 (1998) 963-968
7. Ohsumi J., Sakakibara S., Yamaguchi J., Miyadai K., Yoshioka S., Fujiwara T., et al. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 135 (1994) 2279-2282
8. Szalkowski D., White-Carrington S., Berger J., and Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136 (1995) 1474-1481
9. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4 (1999) 585-595
10. Tamori Y., Masugi J., Nishino N., and Kasuga M. Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51 (2002) 2045-2055
11. Hammarstedt A., Sopasakis V.R., Gogg S., Jansson P.A., and Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48 (2005) 96-104
12. Martin G., Schoonjans K., Staels B., and Auwerx J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137 (1998) S75-80
13. Chao L., Marcus-Samuels B., Mason M.M., Moitra J., Vinson C., Arioglu E., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106 (2000) 1221-1228
14. Albrektsen T., Frederiksen K.S., Holmes W.E., Boel E., Taylor K., and Fleckner J. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes 51 (2002) 1042-1051
15. Furuta M., Yano Y., Gabazza E.C., Araki-Sasaki R., Tanaka T., Katsuki A., et al. Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. Diabetes Res Clin Pract 56 (2002) 159-171
16. Young P.W., Cawthorne M.A., Coyle P.J., Holder J.C., Holman G.D., Kozka I.J., et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44 (1995) 1087-1092
17. Stevenson R.W., McPherson R.K., Persson L.M., Genereux P.E., Swick A.G., Spitzer J., et al. The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet. Diabetes 45 (1996) 60-66
18. Weinstein S.P., Holand A., O'Boyle E., and Haber R.S. Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism 42 (1993) 1365-1369
19. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
20. Govers R., James D.E., and Coster A.C. High-throughput analysis of the dynamics of recycling cell surface proteins. Methods Mol Biol 440 (2008) 129-146
21. Maier V.H., and Gould G.W. Long-term insulin treatment of 3T3-L1 adipocytes results in mis-targeting of GLUT4: implications for insulin-stimulated glucose transport. Diabetologia 43 (2000) 1273-1281
22. Williams D., Hicks S.W., Machamer C.E., and Pessin J.E. Golgin-160 is required for the golgi membrane sorting of the insulin-responsive glucose transporter GLUT4 in adipocytes. Mol Biol Cell 17 (2006) 5346-5355
23. Hernandez R., Teruel T., and Lorenzo M. Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes. Diabetologia 46 (2003) 1618-1628
24. Livingstone C., James D.E., Rice J.E., Hanpeter D., and Gould G.W. Compartment ablation analysis of the insulin-responsive glucose transporter (GLUT4) in 3T3-L1 adipocytes. Biochem J 315 (1996) 487-495
25. Shepherd P.R., and Kahn B.B. Glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus. N Engl J Med 341 (1999) 248-257
26. Abel E.D., Peroni O., Kim J.K., Kim Y.B., Boss O., Hadro E., et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409 (2001) 729-733
27. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 (2005) 356-362
28. Cai H., Reinisch K., and Ferro-Novick S. Coats, tethers, rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. Dev Cell 12 (2007) 671-682
29. van Kerkhof P., Lee J., McCormick L., Tetrault E., Lu W., Schoenfish M., et al. Sorting nexin 17 facilitates LRP recycling in the early endosome. EMBO J 24 (2005) 2851-2861
30. Yonemitsu S., Nishimura H., Shintani M., Inoue R., Yamamoto Y., Masuzaki H., et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50 (2001) 1093-1101
31. Shintani M., Nishimura H., Yonemitsu S., Ogawa Y., Hayashi T., Hosoda K., et al. Troglitazone not only increases GLUT4 but also induces its translocation in rat adipocytes. Diabetes 50 (2001) 2296-2300
32. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100 (1997) 3149-3153
33. Camp H.S., Li O., Wise S.C., Hong Y.H., Frankowski C.L., Shen X., et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49 (2000) 539-547
34. Huang J., Hsia S.H., Imamura T., Usui I., and Olefsky J.M. Annexin II is a thiazolidinedione-responsive gene involved in insulin-induced glucose transporter isoform 4 translocation in 3T3-L1 adipocytes. Endocrinology 145 (2004) 1579-1586
35. Foran P.G., Fletcher L.M., Oatey P.B., Mohammed N., Dolly J.O., and Tavare J.M. Protein kinase B stimulates the translocation of GLUT4 but not GLUT1 or transferrin receptors in 3T3-L1 adipocytes by a pathway involving SNAP-23, synaptobrevin-2, and/or cellubrevin. J Biol Chem 274 (1999) 28087-28095
36. Govers R., Coster A.C., and James D.E. Insulin increases cell surface GLUT4 levels by dose dependently discharging GLUT4 into a cell surface recycling pathway. Mol Cell Biol 24 (2004) 6456-6466
37. Karylowski O., Zeigerer A., Cohen A., and McGraw T.E. GLUT4 is retained by an intracellular cycle of vesicle formation and fusion with endosomes. Mol Biol Cell 15 (2004) 870-882
38. Yang J., and Holman G.D. Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis. Endocrinology 147 (2006) 2728-2736
39. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
40. Nolan J.J., Olefsky J.M., Nyce M.R., Considine R.V., and Caro J.F. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes 45 (1996) 1276-1278
41. Lagathu C., Bastard J.P., Auclair M., Maachi M., Capeau J., and Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311 (2003) 372-379
42. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101 (1998) 1354-1361
43. Peraldi P., Xu M., and Spiegelman B.M. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 100 (1997) 1863-1869